The FY16 Defense Appropriations Act provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
The TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2016. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
Focus Areas: The goal of the FY16 TSCRP is to encourage innovative research aimed at understanding the pathogenesis, and preventing and treating the manifestations of TSC. Within this context, the FY16 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY16 Focus Areas:
Read more »